Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide plus carboplatin/etoposide versus placebo plus carboplatin/etoposide in small cell lung cancer
ISRCTN16174527Phase 3Completed
- Sponsor
- London Lung Cancer Group
- Start
- Apr 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in small cell lung cancer (SCLC) comparing Carboplatin + etoposide + thalidomide with Carboplatin + etoposide + placebo (2 arms). Primary endpoint: Overall survival. Started Apr 2003; status: completed.
02
Drugs
thalidomide
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ISRCTN16174527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16174527.